Zymeworks (NASDAQ:ZYME) Raised to "Strong-Buy" at B. Riley

Key Points

• Zymeworks has been upgraded to a "strong-buy" rating by B. Riley, reflecting positive sentiment from some analysts amidst mixed ratings.
• The company's stock is currently trading at $18.06 with a market cap of $1.36 billion, indicating significant growth potential in the biopharmaceutical sector.
• Despite the favorable upgrade, Zymeworks reported a loss of ($1.14) earnings per share and a negative net margin of 59.96% in its most recent earnings report.

Zymeworks (NASDAQ:ZYME - Get Free Report) was upgraded by stock analysts at B. Riley to a "strong-buy" rating in a report released on Thursday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Zymeworks in a research note on Wednesday. Wall Street Zen raised Zymeworks from a "buy" rating to a "strong-buy" rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy".

Zymeworks Price Performance

Shares of ZYME opened at $18.06 on Thursday. The business has a 50-day moving average of $15.16. The stock has a market cap of $1.36 billion, a PE ratio of -18.62 and a beta of 1.51. Zymeworks has a 1-year low of $9.03 and a 1-year high of $18.35.

Zymeworks (NASDAQ:ZYME - Get Free Report) last released its earnings results on Tuesday, November 8th. The company reported ($1.14) earnings per share for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%. The business had revenue of $4.40 million for the quarter.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.